
Aptiv Solutions Executive Discusses the State of Mobile Health Technology Regulatory
OneMedRadio spoke with Cynthia Nolte, Director, Medical Device Regulatory Services for Aptiv Solutions, about the state of mobile health/health information technology regulatory, clinical trial design for mobile health technology, and what we can expect from future guidelines. The conclusions about regulating a rapidly evolving space — and the case studies that have pioneered this process — are intriguing, and indeed promising.
Read more »
Bioinformatics Part II: Application, Manipulation, and Uses
Or, How I Learned to Stop Worrying and Love Computational Biology.
Read more »
Okairos: Okay After All
On May 29th, 2013, GlaxoSmithKline (GSK) announced the acquisition of Okairos in an all-cash deal worth $325 million US. The Okairos acquisition helps complement the pharma giant’s existing vaccine technology and expertise and will enable GSK to continue its work developing the next generation of vaccines.
Read more »
NanoViricides: Big Things In a Small Package
During an interview with OneMedPlace, President and Chairman of NanoViricides (NNVC) Anil Diwan summed up the influenza treatment market in just a few words: It is like trying to hit a moving target.
Read more »OneMedForumNY 2013, June 26-27
NEW YORK, October 3, 2012 – OneMedPlace has announced programming themes for its 6th Annual OneMedForum, taking place January 7-9th, 2013, at the Sir Francis Drake Hotel in San Francisco.
Read more »
MAPPING THE B.R.A.I.N.
On April 2nd, 2013, U.S. President Barack Obama unveiled the “BRAIN” Initiative, which is short for Brain Research through Advancing Innovative Neurotechnologies. The BRAIN Initiative may be known as the spiritual successor to the Human Genome Project, not only for its desire to understand a mysterious place known to medical science, but for taking its cues from the initial success of the HGP.
Read more »
Atossa Genetics’ Portfolio Can Detect Breast Cancer. But Can These Products Eradicate It?
Atossa Genetics believes it can prevent breast cancer by 2020 — and in the meantime, capture a unique market opportunity — with their novel cellular and molecular diagnostic risk assessment products for early detection. Yet in a burgeoning diagnostics space, and rapid advancement in cancer therapeutics, will this company find a niche?
Read more »White Paper Explores the Amarantus Bioscience Alzheimer’s Disease Diagnostic
Amarantus Bioscience has posted a White Paper exploring the company’s LymPro Alzheimer’s Disease diagnostic, prepared by a member of the company’s Board of Advisors. The Paper discusses the increasing prevalence of Alzheimer’s disease, the clinical and economic advantages of early detection, and why the LymPro Test is poised to potentially become the market leading diagnostic product in the Alzheimer’s space.
Read more »
Caprion’s Proteomic Biomarkers — Diverse Clientele Leads to In-House Pipeline
Montreal-based Caprion has established itself as a leader in the proteomic biomarker discovery field, using its proteomics discovery platform CellCarta® to develop pharmacodynamic biomarkers, disease markers and predictive biomarkers. OneMedRadio spoke with Caprion President and CEO Martin Leblanc about industry trends concerning increased risk factors, securing intellectual property and developing an in vitro diagnostics platform.
Read more »